Drug resistance biomarkers in ovarian cancer: a bibliometric study from 2017 to 2022
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This bibliometric analysis identifies key research trends and potential biomarkers for drug resistance in ovarian cancer. It highlights leading institutions and journals, proposing BCL-2, CHRF, and SNAIL as promising indicators for improved patient outcomes.
Area Of Science
- Oncology
- Biomedical Research
- Bibliometrics
Background
- Ovarian cancer has a high mortality rate, largely due to late diagnosis and chemoresistance.
- Identifying reliable biomarkers for chemoresistance is crucial for improving patient outcomes.
- This study focuses on the scientific literature concerning drug resistance biomarkers in ovarian cancer from 2017-2022.
Purpose Of The Study
- To conduct a bibliometric analysis of research on drug resistance biomarkers in ovarian cancer.
- To identify leading contributors, institutions, and journals in this field.
- To uncover emerging research trends and potential novel biomarkers for chemoresistance.
Main Methods
- A systematic search was performed using "drug resistance biomarker" AND "ovarian cancer" in PubMed.
- Literature published in English between 2017 and 2022 was analyzed.
- The Bibliometrix tool in R was used for bibliometric analysis, including various publication types.
Main Results
- 335 articles were analyzed, with the United States and China as top contributors.
- Huazhong University of Science and Technology and UT MD Anderson Cancer Center were leading institutions.
- Key research themes included gene expression, prognosis, and specific biomarkers like BCL-2, CHRF, SNAIL, miR-363, iASPP, ALDH1, Fzd7, and EZH2.
Conclusions
- This bibliometric analysis provides a comprehensive overview of ovarian cancer drug resistance research.
- It facilitates the identification of collaborative networks and future research directions.
- Proposed biomarkers warrant further investigation for clinical application in ovarian cancer therapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...